Back

Disrupting Pregnane X Receptor Signaling Overcomes Temozolomide Resistance in Glioblastoma via Succisa pratensis-Derived Metabolites

Servidio, F.; Pirovano, F.; Remedia, S.; Pellizzer, C.; Nespoli, M.; Galuzzi, B. G.; Bonanomi, M.; Mallia, S.; Commisso, M.; Guzzo, F.; Gervasoni, C.; Gaglio, D.; Moriggi, M.; Capitanio, D.; Bertoli, G. R.; Giammona, A.; Lo Dico, A.

2026-07-09 cancer biology
10.64898/2026.06.22.733681 bioRxiv
Show abstract

Glioblastoma remains a highly aggressive and therapy-resistant brain tumor, with limited benefit from the current standard-of-care regimen combining surgery, radiotherapy, and temozolomide. Overcoming chemoresistance therefore represents a critical unmet clinical need. Here, we investigate the anticancer potential of Succisa pratensis and its ability to enhance TMZ efficacy in GBM models. Treatment with S. pratensis markedly reduced cell proliferation and migration while significantly increasing sensitivity to TMZ. Integrated multi-omics analyses revealed extensive metabolic rewiring, characterized by suppression of central carbon metabolism and activation of stress-adaptive pathways. Mechanistically, we identify the Pregnane X Receptor, a key regulator of drug metabolism and chemoresistance, as a central node affected by treatment. Although S. pratensis increased PXR expression, this was not accompanied by induction of canonical downstream targets, including MDR1 and ALDH1A1, indicating a functional impairment of PXR transcriptional activity. Consistently, pharmacological inhibition of PXR using the antagonist SPA70 further potentiated the cytotoxic effects of S. pratensis and TMZ. Docking analyses suggest that specific secondary metabolites, including apigenin-derived compounds, may interact with the PXR ligand-binding domain, providing a potential molecular basis for this effect. Collectively, our findings indicate that S. pratensis enhances TMZ efficacy by inducing metabolic vulnerability and functionally impairing PXR signaling. These results highlight the therapeutic potential of plant-derived metabolites as adjuvant strategies to overcome chemoresistance in glioblastoma. Article HighlightsO_LISuccisa pratensis enhances temozolomide efficacy in glioblastoma by reducing proliferation, migration, and clonogenic growth. C_LIO_LIIntegrated proteomic and metabolomic analyses reveal extensive metabolic rewiring, with suppression of central carbon metabolism and induction of stress-adaptive pathways. C_LIO_LIPregnane X Receptor (PXR), a key regulator of chemoresistance, is functionally impaired despite increased expression, resulting in reduced activation of drug-resistance genes. C_LIO_LIPharmacological inhibition of PXR further potentiates the antitumor effects of Succisa pratensis and temozolomide, promoting apoptotic cell death. C_LIO_LIApigenin-derived metabolites show high affinity for the PXR ligand-binding domain and emerge as promising candidates to overcome temozolomide resistance in glioblastoma. C_LI

Matching journals

The top 15 journals account for 50% of the predicted probability mass.

1
Cell Chemical Biology
94 papers in training set
Top 0.1%
7.2%
2
Nature Communications
5641 papers in training set
Top 27%
5.5%
3
Neuro-Oncology
36 papers in training set
Top 0.2%
4.8%
4
Scientific Reports
3612 papers in training set
Top 29%
3.5%
5
EMBO Molecular Medicine
95 papers in training set
Top 0.2%
3.4%
6
International Journal of Molecular Sciences
494 papers in training set
Top 4%
3.2%
7
Advanced Science
286 papers in training set
Top 2%
3.2%
8
Neoplasia
23 papers in training set
Top 0.1%
3.2%
9
Cell Death & Disease
21 papers in training set
Top 0.1%
3.2%
10
Molecular Oncology
55 papers in training set
Top 0.3%
2.8%
11
Frontiers in Oncology
103 papers in training set
Top 1%
2.6%
12
Communications Biology
993 papers in training set
Top 7%
2.6%
13
Cell Reports
1498 papers in training set
Top 15%
2.4%
14
iScience
1154 papers in training set
Top 11%
2.4%
15
Cell Communication and Signaling
51 papers in training set
Top 0.4%
2.1%
50% of probability mass above
16
Biochemical Pharmacology
20 papers in training set
Top 0.1%
2.1%
17
eBioMedicine
183 papers in training set
Top 2%
2.0%
18
eLife
5828 papers in training set
Top 50%
1.7%
19
Molecular Cancer Therapeutics
40 papers in training set
Top 0.5%
1.7%
20
PLOS ONE
5266 papers in training set
Top 50%
1.7%
21
Cell Reports Medicine
153 papers in training set
Top 2%
1.7%
22
Redox Biology
70 papers in training set
Top 0.8%
1.3%
23
European Journal of Pharmacology
15 papers in training set
Top 0.3%
1.3%
24
International Journal of Biological Sciences
10 papers in training set
Top 0.1%
1.1%
25
Cell Death Discovery
58 papers in training set
Top 1.0%
1.1%
26
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 35%
1.1%
27
Life Sciences
27 papers in training set
Top 0.8%
1.1%
28
Metabolites
53 papers in training set
Top 0.7%
1.1%
29
Journal of Medicinal Chemistry
77 papers in training set
Top 0.8%
1.0%
30
Biomedicine & Pharmacotherapy
42 papers in training set
Top 1%
1.0%